300016 北陆药业
午间休市 12-30 11:30:00
资讯
新帖
简况
股市必读：北陆药业（300016）12月26日董秘有最新回复
证券之星 · 12-29 04:25
股市必读：北陆药业（300016）12月26日董秘有最新回复
北陆药业：取得枸橼酸西地那非口崩片注册证书
证券之星 · 12-26
北陆药业：取得枸橼酸西地那非口崩片注册证书
北陆药业(300016.SZ)获得枸橼酸西地那非口崩片《药品注册证书》
智通财经 · 12-25
北陆药业(300016.SZ)获得枸橼酸西地那非口崩片《药品注册证书》
北陆药业拟募资1.59亿元投建亳州化药生产基地与智能仓库项目
中金财经 · 12-24
北陆药业拟募资1.59亿元投建亳州化药生产基地与智能仓库项目
北陆药业（300016）披露2025年度以简易程序向特定对象发行股票预案（修订稿），12月23日股价下跌0.25%
证券之星 · 12-23
北陆药业（300016）披露2025年度以简易程序向特定对象发行股票预案（修订稿），12月23日股价下跌0.25%
北陆药业(300016.SZ)获吡格列酮二甲双胍片药品注册证书
智通财经 · 12-12
北陆药业(300016.SZ)获吡格列酮二甲双胍片药品注册证书
北陆药业：截至2025年9月末公司股东总户数为42,945户
证券之星 · 12-03
北陆药业：截至2025年9月末公司股东总户数为42,945户
北陆药业：九味镇心颗粒是公司独家品种
证券之星 · 11-13
北陆药业：九味镇心颗粒是公司独家品种
北陆药业：钆布醇注射剂中选第十一批集采
证券之星 · 11-13
北陆药业：钆布醇注射剂中选第十一批集采
北陆药业（300016）披露为全资子公司提供担保议案，11月12日股价上涨2.96%
证券之星 · 11-12
北陆药业（300016）披露为全资子公司提供担保议案，11月12日股价上涨2.96%
北陆药业(300016.SZ)获得碘美普尔注射液药品注册证书
智通财经 · 11-10
北陆药业(300016.SZ)获得碘美普尔注射液药品注册证书
北陆药业最新公告：钆布醇注射剂拟中选第十一批全国药品集中采购
证券之星 · 10-29
北陆药业最新公告：钆布醇注射剂拟中选第十一批全国药品集中采购
北陆药业(300016)9月30日股东户数4.29万户，较上期减少2.23%
证券之星 · 10-29
北陆药业(300016)9月30日股东户数4.29万户，较上期减少2.23%
图解北陆药业三季报：第三季度单季净利润同比增长192.80%
证券之星 · 10-28
图解北陆药业三季报：第三季度单季净利润同比增长192.80%
10月24日增减持汇总：北陆药业等7家公司减持 暂无A股增持（表）
新浪证券 · 10-24
10月24日增减持汇总：北陆药业等7家公司减持 暂无A股增持（表）
北陆药业最新公告：股东三峡油漆拟减持不超1.78%公司股份
证券之星 · 10-24
北陆药业最新公告：股东三峡油漆拟减持不超1.78%公司股份
北陆药业（300016）披露召开2025年第三次临时股东会提示性公告，10月13日股价下跌1.28%
证券之星 · 10-13
北陆药业（300016）披露召开2025年第三次临时股东会提示性公告，10月13日股价下跌1.28%
北陆药业(300016.SZ)拟以简易程序定增募资不超3亿元
智通财经 · 09-26
北陆药业(300016.SZ)拟以简易程序定增募资不超3亿元
【机构调研记录】国联基金调研北陆药业、悍高集团
证券之星 · 09-22
【机构调研记录】国联基金调研北陆药业、悍高集团
【私募调研记录】神农投资调研北陆药业
证券之星 · 09-22
【私募调研记录】神农投资调研北陆药业
加载更多
公司概况
公司名称：
北京北陆药业股份有限公司
所属行业：
医药制造业
上市日期：
2009-10-30
主营业务：
北京北陆药业股份有限公司的主营业务是对比剂制剂及原料药、中枢神经类和降糖类药品的研发、生产与销售。公司的主要产品是化学仿制药、中成药、原料药。
发行价格：
17.86
{"stockData":{"symbol":"300016","market":"SZ","secType":"STK","nameCN":"北陆药业","latestPrice":8.03,"timestamp":1767068292000,"preClose":8.01,"halted":0,"volume":2749466,"delay":0,"changeRate":0.0025,"floatShares":562000000,"shares":563000000,"eps":0.0594,"marketStatus":"午间休市","change":0.02,"latestTime":"12-30 11:30:00","open":7.99,"high":8.05,"low":7.96,"amount":21989200,"amplitude":0.0112,"askPrice":8.04,"askSize":176,"bidPrice":8.03,"bidSize":188,"shortable":0,"etf":0,"ttmEps":0.0594,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767070800000},"marketStatusCode":3,"adr":0,"adjPreClose":8.01,"symbolType":"stock","openAndCloseTimeList":[[1767058200000,1767065400000],[1767070800000,1767078000000]],"highLimit":8.81,"lowLimit":7.21,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":562873163,"isCdr":false,"pbRate":2.04,"roa":"--","peRate":135.185185,"roe":"2.46%","epsLYR":0.03,"committee":-0.217339,"marketValue":4520000000,"turnoverRate":0.0049,"status":0,"floatMarketCap":4514000000},"requestUrl":"/m/hq/s/300016","defaultTab":"news","newsList":[{"id":"2595503279","title":"股市必读：北陆药业（300016）12月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595503279","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595503279?lang=zh_cn&edition=full","pubTime":"2025-12-29 04:25","pubTimestamp":1766953511,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，北陆药业报收于8.09元，下跌0.12%，换手率1.64%，成交量9.22万手，成交额7556.41万元。董秘最新回复投资者： 请问贵司取得的枸橼酸西地那非的药，这个药的利润率是否高于公司目前其他产品的平均利润率?公司于近期取得枸橼酸西地那非口崩片的《药品注册证书》，目前正积极开展新产品上市的各项准备工作，并尽快将产品推向市场。当日关注点来自交易信息汇总：12月26日主力资金净流出69.0万元，散户资金净流入203.05万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900001646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0060","BK0239","300016","BK0042"],"gpt_icon":0},{"id":"2594490267","title":"北陆药业：取得枸橼酸西地那非口崩片注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2594490267","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594490267?lang=zh_cn&edition=full","pubTime":"2025-12-26 16:54","pubTimestamp":1766739247,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业(300016)12月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司取得的枸橼酸西地那非的药，这个药的利润率是否高于公司目前其他产品的平均利润率? 这款药品将给公司明年带来多大的业绩提升?北陆药业回复：感谢您的关注。公司于近期取得枸橼酸西地那非口崩片的《药品注册证书》，目前正积极开展新产品上市的各项准备工作，并尽快将产品推向市场。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600023372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0060","BK0046","300016"],"gpt_icon":0},{"id":"2594238146","title":"北陆药业(300016.SZ)获得枸橼酸西地那非口崩片《药品注册证书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2594238146","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594238146?lang=zh_cn&edition=full","pubTime":"2025-12-25 15:53","pubTimestamp":1766649199,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北陆药业(300016.SZ)发布公告，近日，公司收到国家药品监督管理局核准签发的枸橼酸西地那非口崩片的《药品注册证书》。西地那非为5型磷酸二酯酶选择性抑制剂，用于治疗勃起功能障碍，具有起效迅速、疗效确切等优势。枸橼酸西地那非口崩片为美国辉瑞公司开发的西地那非迭代剂型，2019年在中国批准进口。枸橼酸西地那非口崩片无需患者饮水、口腔放置数秒即可崩解、起效时间快，可满足该类患者对于服用方便、起效快、隐私性好的口服药物的需求，为患者提供更灵活多样的用药选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385813.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"北陆药业(300016.SZ)获得枸橼酸西地那非口崩片《药品注册证书》","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0239","BK0042","300016","BK0060"],"gpt_icon":0},{"id":"2593044159","title":"北陆药业拟募资1.59亿元投建亳州化药生产基地与智能仓库项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2593044159","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593044159?lang=zh_cn&edition=full","pubTime":"2025-12-24 08:06","pubTimestamp":1766534773,"startTime":"0","endTime":"0","summary":"中访网数据 北京北陆药业股份有限公司近日发布公告，计划以简易程序向特定对象发行股票，募集资金总额不超过1.59亿元，扣除发行费用后全部用于其全资子公司陆芝葆药业有限公司在安徽省亳州市谯城区实施的“陆芝葆化药生产车间与智能综合仓库项目”。该项目总投资额约为3.93亿元，旨在扩大公司在高端化学仿制药领域的产能并建设现代化智能仓储体系。化药生产车间建设周期预计为36个月，智能仓库建设周期为12个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251224/31886132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0046","BK0060","BK0239","BK0042","300016"],"gpt_icon":0},{"id":"2593928416","title":"北陆药业（300016）披露2025年度以简易程序向特定对象发行股票预案（修订稿），12月23日股价下跌0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593928416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593928416?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:46","pubTimestamp":1766501197,"startTime":"0","endTime":"0","summary":"截至2025年12月23日收盘，北陆药业报收于8.06元，较前一交易日下跌0.25%，最新总市值为45.37亿元。该股当日开盘8.11元，最高8.11元，最低7.98元，成交额达4399.36万元，换手率为0.97%。近日，北京北陆药业股份有限公司发布《2025年度以简易程序向特定对象发行股票预案（修订稿）》。公告显示，公司拟以简易程序向特定对象发行股票，募集资金总额不超过15,900.00万元，用于陆芝葆化药生产车间与智能综合仓库项目。本次发行不会导致公司控制权变化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300041144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","300016","BK0042","BK0060"],"gpt_icon":0},{"id":"2590866576","title":"北陆药业(300016.SZ)获吡格列酮二甲双胍片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590866576","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590866576?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:46","pubTimestamp":1765525578,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北陆药业(300016.SZ)公告，公司收到国家药品监督管理局核准签发的吡格列酮二甲双胍片(15mg/500mg)的《药品注册证书》。本品适用于在饮食控制和运动的基础上，用于目前使用盐酸吡格列酮和盐酸二甲双胍联合治疗的2型糖尿病患者或单用盐酸二甲双胍治疗后血糖控制不佳的2型糖尿病患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"北陆药业(300016.SZ)获吡格列酮二甲双胍片药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300016","BK0046","BK0060","BK0042"],"gpt_icon":0},{"id":"2588701165","title":"北陆药业：截至2025年9月末公司股东总户数为42,945户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588701165","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588701165?lang=zh_cn&edition=full","pubTime":"2025-12-03 17:03","pubTimestamp":1764752590,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业(300016)12月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止到2025年11月30日，公司股东人数是多少？北陆药业回复：感谢您的关注。截至2025年9月末公司股东总户数为42,945户，截至2025年12月末的公司股东总户数将在《2025年年度报告》中披露，敬请关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120300025598.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0060","BK0239","BK0042","300016"],"gpt_icon":0},{"id":"2583559094","title":"北陆药业：九味镇心颗粒是公司独家品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2583559094","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583559094?lang=zh_cn&edition=full","pubTime":"2025-11-13 15:45","pubTimestamp":1763019948,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业(300016)11月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问九味镇心颗粒是否为北陆药业独家品种？北陆药业回复：感谢您的关注。九味镇心颗粒是公司自主研发的中药创新药，是国家食品药品监督管理总局批准治疗广泛性焦虑症的纯中药制剂，医保品种，也是公司的独家品种。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300022882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0060","BK0046","BK0239","300016"],"gpt_icon":0},{"id":"2583559055","title":"北陆药业：钆布醇注射剂中选第十一批集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2583559055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583559055?lang=zh_cn&edition=full","pubTime":"2025-11-13 15:45","pubTimestamp":1763019936,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业11月13日在投资者关系平台上答复投资者关心的问题。我想查询贵公司在国家组织药品集中采购中的中选药品的销售额这一数据，在哪里可以获取呢？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300022852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016","BK0060","BK0042","BK0046","BK0239"],"gpt_icon":0},{"id":"2582377377","title":"北陆药业（300016）披露为全资子公司提供担保议案，11月12日股价上涨2.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582377377","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582377377?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:14","pubTimestamp":1762956866,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，北陆药业报收于9.05元，较前一交易日上涨2.96%，最新总市值为50.94亿元。该股当日开盘8.76元，最高9.07元，最低8.73元，成交额达3.22亿元，换手率为6.38%。公司近日发布公告称，将于2025年11月13日召开2025年第四次临时股东会，会议由董事会召集，现场会议时间为当日14:30，网络投票时间为当日9:15至15:00。本次股东会将审议关于为全资子公司陆芝葆药业有限公司提供担保的议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0060","BK0239","BK0042","300016"],"gpt_icon":0},{"id":"2582231498","title":"北陆药业(300016.SZ)获得碘美普尔注射液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2582231498","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582231498?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:22","pubTimestamp":1762762978,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 北陆药业 发布公告，近日，公司收到国家药品监督管理局核准签发的碘美普尔注射液《药品注册证书》。碘美普尔注射液由意大利Bracco研制，属于一种非离子型单体X射线造影剂。碘美普尔注射液已纳入国家医保乙类目录。根据米内网数据显示，近年来在中国三大终端六大市场的销售额均以两位数的增速增长，2024年超过11亿元，同比增长约32%;2025年一季度超过3亿元，同比增长约39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300016","BK0060","BK0046","BK0042"],"gpt_icon":0},{"id":"2579549973","title":"北陆药业最新公告：钆布醇注射剂拟中选第十一批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2579549973","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579549973?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:47","pubTimestamp":1761731257,"startTime":"0","endTime":"0","summary":"北陆药业公告称，公司钆布醇注射剂拟中选第十一批全国药品集中采购。该产品于2022年4月和2024年4月分别获得国家药品监督管理局核准签发的《药品注册证书》及《药品补充申请批准通知书》。随着中选结果的执行，钆布醇注射剂有望快速打开市场，提升公司对比剂产品的市场份额和品牌影响力。但采购合同签订等后续事项以及带量采购后市场销售执行情况存在不确定性，公司将密切关注进展并及时披露信息。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900037427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0046","300016","BK0042"],"gpt_icon":0},{"id":"2579980978","title":"北陆药业(300016)9月30日股东户数4.29万户，较上期减少2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579980978","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579980978?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:32","pubTimestamp":1761730357,"startTime":"0","endTime":"0","summary":"证券之星消息，近日北陆药业披露，截至2025年9月30日公司股东户数为4.29万户，较6月30日减少980.0户，减幅为2.23%。在化学制药行业个股中，北陆药业股东户数高于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.38万户。从股价来看，2025年6月30日至2025年9月30日，北陆药业区间跌幅为10.22%，在此期间股东户数减少980.0户，减幅为2.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900036310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016","BK0239","BK0060","BK0042","BK0046"],"gpt_icon":0},{"id":"2578955108","title":"图解北陆药业三季报：第三季度单季净利润同比增长192.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578955108","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578955108?lang=zh_cn&edition=full","pubTime":"2025-10-28 19:35","pubTimestamp":1761651352,"startTime":"0","endTime":"0","summary":"证券之星消息，北陆药业2025年三季报显示，公司主营收入8.73亿元，同比上升19.59%；归母净利润4417.69万元，同比上升81.1%；扣非净利润3367.58万元，同比上升33.53%；其中2025年第三季度，公司单季度主营收入2.88亿元，同比上升12.78%；单季度归母净利润1421.0万元，同比上升192.8%；单季度扣非净利润393.82万元，同比下降35.49%；负债率26.47%，投资收益674.49万元，财务费用3558.54万元，毛利率45.87%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800036117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300016"],"gpt_icon":0},{"id":"2577125095","title":"10月24日增减持汇总：北陆药业等7家公司减持 暂无A股增持（表）","url":"https://stock-news.laohu8.com/highlight/detail?id=2577125095","media":"新浪证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577125095?lang=zh_cn&edition=full","pubTime":"2025-10-24 21:37","pubTimestamp":1761313020,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 据统计，10月24日，盘后北陆药业、艾比森、中科飞测、利扬芯片、起帆电缆、尚太科技、华阳集团等7家A股上市公司披露减持情况。当日暂无上市公司披露增持情况。\n\n\n新浪声明：此消息系转载自新浪合作媒体，新浪网登载此文出于传递更多信息之目的，并不意味着赞同其观点或证实其描述。文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-10-24/doc-infuzhch6694982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159982","BK0060","BK0046","399300","BK0042","300016","BK0239"],"gpt_icon":0},{"id":"2577181590","title":"北陆药业最新公告：股东三峡油漆拟减持不超1.78%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2577181590","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577181590?lang=zh_cn&edition=full","pubTime":"2025-10-24 18:49","pubTimestamp":1761302964,"startTime":"0","endTime":"0","summary":"北陆药业(300016.SZ)公告称，持股5%以上股东三峡油漆计划自公告披露之日起15个交易日后的3个月内，以集中竞价、大宗交易或两者相结合的方式减持不超过1,000万股公司股份，占公司总股本比例1.78%，减持原因为提高资产流动性和使用效率。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400034145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0060","BK0239","BK0042","300016"],"gpt_icon":0},{"id":"2575340701","title":"北陆药业（300016）披露召开2025年第三次临时股东会提示性公告，10月13日股价下跌1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575340701","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575340701?lang=zh_cn&edition=full","pubTime":"2025-10-13 22:33","pubTimestamp":1760366003,"startTime":"0","endTime":"0","summary":"截至2025年10月13日收盘，北陆药业报收于8.51元，较前一交易日下跌1.28%，最新总市值为47.9亿元。近日，北京北陆药业股份有限公司发布关于召开2025年第三次临时股东会的提示性公告。公告称，公司将于2025年10月14日召开2025年第三次临时股东会，现场会议时间为当日14:30，网络投票时间为同日9:15至15:00。会议由公司董事会召集，股权登记日为2025年10月9日。现场登记时间为2025年10月10日至13日，异地股东可通过传真或信函方式登记。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300025370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0042","BK0046","300016","BK0239"],"gpt_icon":0},{"id":"2570007075","title":"北陆药业(300016.SZ)拟以简易程序定增募资不超3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570007075","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570007075?lang=zh_cn&edition=full","pubTime":"2025-09-26 19:13","pubTimestamp":1758885218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，北陆药业(300016.SZ)披露2025年度以简易程序向特定对象发行股票预案，公司拟向不超过35名(含)发行股票，发行价格不低于定价基准日前二十个交易日公司股票交易均价的百分之八十，发行数量按照募集资金总额除以发行价格确定，且不超过本次发行前公司总股本的30%。本次以简易程序向特定对象发行股票的募集资金总额不超过3亿元(含本数)，在扣除相关发行费用后的募集资金净额将全部投资于陆芝葆化药生产车间与智能综合仓库项目、新建100吨碘美普尔、50吨碘比醇原料药生产线技改项目、补充流动资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1350028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0046","BK0060","BK0239","BK0042","300016"],"gpt_icon":0},{"id":"2569276569","title":"【机构调研记录】国联基金调研北陆药业、悍高集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2569276569","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569276569?lang=zh_cn&edition=full","pubTime":"2025-09-22 08:01","pubTimestamp":1758499291,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月19日披露的机构调研信息，国联基金近期对2家上市公司进行了调研，相关名单如下：1）北陆药业 调研纪要：2025年上半年，公司实现营业收入58,420.89万元，同比增长23.27%；归母净利润2,996.69万元，同比增长53.35%。2）悍高集团 调研纪要：公司未来三年将全面推进产品创新、渠道下沉、品牌传播及海外市场布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200001825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0256","BK0046","300016","001221","BK0042"],"gpt_icon":0},{"id":"2569593276","title":"【私募调研记录】神农投资调研北陆药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2569593276","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569593276?lang=zh_cn&edition=full","pubTime":"2025-09-22 08:00","pubTimestamp":1758499257,"startTime":"0","endTime":"0","summary":"根据市场公开信息及9月19日披露的机构调研信息，知名私募神农投资近期对1家上市公司进行了调研，相关名单如下：1）北陆药业 调研纪要：2025年上半年，公司实现营业收入58,420.89万元，同比增长23.27%；归母净利润2,996.69万元，同比增长53.35%。研发投入3,902.73万元，同比增长10.09%，在研项目34项。xa0自成立以来，神农投资8次荣膺金牛奖，及金樽奖、英华奖、《福布斯》最佳私募基金经理等奖项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025092200001772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0042","BK0046","300016"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767068342312,"stockEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0599},{"period":"6month","weight":-0.1751},{"period":"1year","weight":0.2529},{"period":"ytd","weight":0.3016}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1478},{"period":"1year","weight":0.1662},{"period":"ytd","weight":0.183}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京北陆药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42945人(较上一季度减少2.23%)","perCapita":"13089股","listingDate":"2009-10-30","address":"北京市密云区水源西路3号","registeredCapital":"56287万元","survey":" 北京北陆药业股份有限公司的主营业务是对比剂制剂及原料药、中枢神经类和降糖类药品的研发、生产与销售。公司的主要产品是化学仿制药、中成药、原料药。","listedPrice":17.86},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供北陆药业(300016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"北陆药业,300016,北陆药业股票,北陆药业股票老虎,北陆药业股票老虎国际,北陆药业行情,北陆药业股票行情,北陆药业股价,北陆药业股市,北陆药业股票价格,北陆药业股票交易,北陆药业股票购买,北陆药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"北陆药业(300016)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供北陆药业(300016)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}